Hims & Hers Stock Is Due for a Crash Diet. The Weight-Loss Drug Surge Is Fading Fast.
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.
Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
Why Hims & Hers Health Stock Just Popped
Roller-coaster healthcare stock Hims & Hers Health ( HIMS -1.34%), whose stock got devastated last week by worries that it ...
Citi Sticks to Sell Rating on Hims & Hers (HIMS) Stock as FDA Ruling Clouds Outlook
Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...
Hims & Hers shares plunge as looming curbs on drug compounding cloud forecast
Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth provider's lofty sales forecast on Tuesday amid looming restrictions on ...
Hims & Hers Stocks Sinks Despite Huge Revenue Growth. Is This a Buying Opportunity in the Stock?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
This Could Be a Huge Blow to Hims & Hers Health Stock
Hims & Hers Health (NYSE: HIMS) has been a top healthcare stock to own over the past five years, soaring by around 350% ...
Hims & Hers' Weight-Loss Bet Hits a Wall--Is the Stock's $6 Billion Surge About to Unravel?
With the FDA shutting down its key revenue stream, Hims faces a tough road ahead--can it justify its valuation?
Hims & Hers Stock (HIMS) Soars on Plans to Shutter Acne Treatment Unit
Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of ...